Share This Article:

Clinical Analysis of Bevacizumab Plus FOLFIRI Regimen as Front-Line Therapy for Chinese Patients with Advanced Colorectal Cancer

Abstract Full-Text HTML Download Download as PDF (Size:69KB) PP. 470-474
DOI: 10.4236/jct.2011.24063    4,281 Downloads   7,381 Views  

ABSTRACT

The study was designed to evaluate the therapeutic and side effects of Bevacizumab plus FOLFIRI regimen as front-line therapy for Chinese patients with advanced colorectal cancer. A total of 15 previously untreated patients with advanced colorectal cancer received Bevacizumab plus FOLFIRI regimen as font-line therapy, in detail, irinotecan 180 mg/m2 was given intravenously on day1, then calcium folinate (CF) 200 mg/m2, F-fluorouracil (5-Fu) 400 mg/m2 given in bolus immediately after CF, day 1 - 2; 5-Fu 600 mg/2 given continuously after bolus for 22 hours on day1, day2; Bevacizumab was given intravenously at dosage of 5 mg/kg, on day-1. Therapeutic and side effects were evaluated at least after four cycles of treatment. The results showed that all the cases among the group were valid for response evaluation, with CR 0, PR 10, SD 3, and PD 2. The response rate is 66.7% and median time to progression (mTTP) was 10.6 months. The main toxicities were bone marrow suppression, nausea and vomiting, stomach pain and diarrhea; there was no chemotherapy-related death. The data suggested that the combination regimen with Bevacizumab plus FOLFIRI regimen was effective as front-line therapy for Chinese patients with advanced colorectal cancer, and the side effects were tolerable and manageable.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

X. Zhou, J. Yang, J. Liang, P. Li, Y. Wu, X. Fan and X. Li, "Clinical Analysis of Bevacizumab Plus FOLFIRI Regimen as Front-Line Therapy for Chinese Patients with Advanced Colorectal Cancer," Journal of Cancer Therapy, Vol. 2 No. 4, 2011, pp. 470-474. doi: 10.4236/jct.2011.24063.

References

[1] H. Y. Luo, Y. H. Li, L. Zhang, W. Q. Jiang, Y. X. Shi, F. Wang, Y. J. He and R. H. Xu, “Efficacy of CPT-11 Combined 5-FU/CF (FOLFIRI) Regimen on Advanced Colorectal Cancer,” Chinese Journal of Cancer, Vol. 26, No. 8, 2007, pp. 905-908.
[2] J. Li, “Application of Monoclonal Antibody in Combination with Irinotecan in the Treatment of Colorectal Cancer,” Chinese Journal of Oncology, Vol. 28, No. 10, 2006, pp. 796-797.
[3] J. Ma, S. K. Qin and Q. Y. Zhang, “Album of Chinese Education in Clinical Oncology,” Heilongjiang Science and Technology Press, Haerbin, 2007, pp. 302-306.
[4] S. P. Khosravi and P. I. Fernández, “Tumoral Angiogenesis: Review of the Literature,” Cancer Investigation, Vol. 26, No. 1, 2008, pp. 104-108. doi:10.1080/07357900701662509
[5] B. J. Giantonio, P. J. Catalano, N. J. Meropol, P. J. O’Dwyer, E. P. Mitchell, S. R. Alberts, M. A. Schwartz and A. B. Benson, “Bevacizumab in Combination with Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results from the Eastern Cooperative Oncology Group Study E3200,” Journal of Clinical Oncology, Vol. 25, No. 12, 2007, pp. 1539-1544.
[6] C. Emmanouilides, G. Sfakiotaki, N. Androulakis, K. Kalbakis, C. Christophylakis, A. Kalykaki, L. Vamvakas, A. Kotsakis, S. Agelaki, E. Diamandidou, N. Touroutoglou, A. Chatzidakis, V. Georgoulias, D. Mavroudis and J. Souglakos, “Front-Line Bevacizumab in Combination with Oxaliplatin, Leucovorin And 5-Fluorouracil (FOLFOX) in Patients with Metastatic Colorectal Cancer: A Multicenter Phase II Study,” BMC Cancer, Vol. 7, 2007, p. 91.
[7] L. B. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T. S. Yang, F. Rivera, F. Couture, F. Sirzén and J. Cassidy, “Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,” Journal of Clinical Oncology, Vol. 26, No. 12, 2008, pp. 2013-2019.
[8] H. I. Hurwitz, L. Fehrenbacher, J. D. Hainsworth, W. Heim, J. Berlin, E. Holmgren, J. Hambleton, W. F. Novotny and F. Kabbinavar, “Bevacizumab in Combination with Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer,” Journal of Clinical Oncology, Vol. 23, No. 15, 2005, pp. 3502-3508.
[9] H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross and F. Kabbinavar, “Bevacizumab Plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer,” The New England Journal of Medicine, Vol. 350, 2004, pp. 2335-2342.
[10] D. R. Gandara, R. Sangha and A. M. Davies, “Bevacizumab: Optimal Dose, Schedule, and Duration of Therapy,” Clinical Lung Cancer, Vol. 8, No. 9, 2007, pp. 522-523.
[11] C. Tournigand, T. André, E. Achille, G. Lledo, M. Flesh, D. Mery-Mignard, E. Quinaux, C. Couteau, M. Buyse, G. Ganem, B. Landi, P. Colin, C. Louvet and A. de Gramont, “FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study,” Journal of Clinical Oncology, Vol. 22, 2004, pp. 229-237.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.